Immuneering Corporation (NASDAQ: IMRX) stock had a sharp increase when positive results from a clinical trial were revealed. As of the most recent pre-market check, IMRX shares were up 55.51% on the charts, trading at $3.67.
Positive Outcomes for the Treatment of Pancreatic Cancer
Immuneering reported encouraging results from three pancreatic cancer arms of its Phase 2a study for its main product, IMM-1-104. IMRX also disclosed intentions to add three more combination arms to the experiment.
Unlike traditional MEK inhibitors, which primarily target a minority of patients with BRAF-driven malignancies, IMM-1-104 is intended to boost tolerance and broaden its indications to include RAS-mutated tumors, which are frequently found in pancreatic cancer.
In patients with first-line pancreatic cancer, IMM-1-104 with modified gemcitabine/nab-paclitaxel resulted in an updated objective response rate (ORR) of 43% and a disease control rate (DCR) of 86%, according the most recent data. Immuneering is getting ready for a possible pivotal clinical study and intends to release further findings by Q2 2025.
Encouraging Data Across Treatment Arms
Initial findings from IMM-1-104 combined with modified FOLFIRINOX in first-line pancreatic cancer patients indicated target lesion shrinkage in all evaluable cases, including one remarkable case of complete tumor reduction.
The monotherapy arm of IMM-1-104 for second-line pancreatic cancer also demonstrated clear efficacy, highlighted by a partial response with a 67% reduction in the target lesion. These results underscore IMM-1-104’s potential to enhance treatment outcomes when used alongside current therapies.
Future Expansion and Differentiation
Immuneering’s data further reinforced the distinct safety profile of IMM-1-104, designed for superior tolerability and activity compared to existing MEK inhibitors, which generated approximately $2.4 billion in sales in 2023.
IMRX announced plans to expand the Phase 2a trial by including IMM-1-104 with a BRAF inhibitor for BRAF-mutant melanoma and with an immune checkpoint inhibitor for melanoma and non-small cell lung cancer (NSCLC). These new arms are expected to commence in 2025.
With these advancements, Immuneering is charting a path toward addressing unmet needs in pancreatic cancer and offering a more effective and tolerable alternative for existing MEK-inhibitor-treated conditions.
